PACT-Q2 scores of NVAF patients switching from VKA to dabigatran
| PACT-Q2 dimensions | N | Mean±SD | P value of paired t-test compared with baseline | P value of paired t-test compared with visit 2 |
| Convenience dimension score | ||||
| Baseline | 377 | 71.4±21.8 | – | – |
| Visit 2 | 317 | 79.6±18.1 | <0.0001 | – |
| Visit 3 | 266 | 82.0±16.8 | <0.0001 | 0.1234 |
| Satisfaction dimension score | ||||
| Baseline | 377 | 61.0±13.3 | – | – |
| Visit 2 | 317 | 63.2±14.6 | 0.0174 | – |
| Visit 3 | 266 | 64.4±14.7 | 0.0004 | 0.9740 |
NVAF, non-valvular atrial fibrillation; PACT-Q2, Perception on Anticoagulant Treatment Questionnaire-2; VKA, vitamin K antagonist.